Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply

Affiliations

Shukui Qin. Lancet. 2024.

. 2024 Oct 12;404(10461):1405-1406.

doi: 10.1016/S0140-6736(24)01773-2.

¹ Nanjing Tianyinshan Hospital of China Pharmaceutical University, Nanjing 211100, China. Electronic address: qinsk@csco.org.cn.

No abstract available

Comment in

Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
Li H, Yan J, Han T. Li H, et al. Lancet. 2024 Oct 12;404(10461):1403-1404. doi: 10.1016/S0140-6736(24)01770-7. Lancet. 2024. PMID: 39396344 No abstract available.
Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
Wang JK, Liao R. Wang JK, et al. Lancet. 2024 Oct 12;404(10461):1404-1405. doi: 10.1016/S0140-6736(24)01771-9. Lancet. 2024. PMID: 39396345 No abstract available.
Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
Ponvilawan B, Roth MT. Ponvilawan B, et al. Lancet. 2024 Oct 12;404(10461):1405. doi: 10.1016/S0140-6736(24)01772-0. Lancet. 2024. PMID: 39396347 No abstract available.